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The detrimental effect of smoking on population health has been 
apparent since the early 1900s, when a relationship between increased 
prevalence of smoking and increased incidence of lung cancer, 
previously uncommon, was identified.[1,2] Since then, numerous 
studies have highlighted the relationships between smoking and 
non-communicable diseases including cardiorespiratory disease, 
autoimmune disease, subfertility, malignancy, cerebrovascular disease 
and poor fetomaternal outcomes.[2-6]
South Africa (SA)’s first burden of disease report in 2000 highlighted 
the quadruple burden of disease the country faces and the need for 
a multifaceted approach to improving health that includes managing 
modifiable risk factors, particularly smoking.[7] It was reported that 
in SA in 2000, smoking accounted for 8.5% of all deaths (and 13% of 
deaths in adults aged >35 years) and 3.7 - 4.3% of disability-adjusted 
life-years due to lung and other cancers, cardiovascular disease, 
chronic obstructive pulmonary disease (COPD), tuberculosis and 
other medical conditions.[8] South Africa has an estimated 7.2 million 
adults living with HIV, 60% of whom are co-infected with TB, with 
61% of adults on antiretroviral therapy.[9] In addition, both smoking 
and TB increase the risk of COPD.[10-13] However, individuals who 
quit smoking successfully lower their risk with every year after 
cessation. Furthermore, those who manage to quit before the age of 
45 have the same life expectancy as those who have never smoked.[14]
Many low- and middle-income countries (LMICs) have made 
significant efforts to minimise adverse health outcomes due to smoking, 
with legislation restricting tobacco use, advertising and trade following 
the World Health Organization (WHO) MPOWER strategy.[15] Formal 
cessation programmes mainly exist in high-income countries, which 
equate to ~15% of the world’s population able to access cessation 
support.[16] Very few data exist on formal cessation programmes 
provided in low-income settings or on how applicable cessation 
strategies developed in high-income settings are to low-income 
countries.[16,17] Furthermore, smoking cessation pharmacotherapy such 
as nicotine replacement therapy (NRT), although on the WHO 
essential medicine list, is not always available to smokers.[18,19] This 
is particularly true in SA, where, although it is classed as a middle-
income country, no smoking cessation pharmacotherapy is available to 
smokers accessing public health services.
A combination of behavioural therapy and pharmacological 
support is regarded as the interventional strategy with the highest 
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Background. South Africa, ranked as the world’s second most stressful country to live in, has an estimated 7 million smokers. A dedicated 
smoking cessation clinic established at Groote Schuur Hospital, Cape Town, provides the only clinical service and training centre in the 
country.
Objectives. To evaluate the smokers attending the clinic, in order to better understand the requirements of smoking cessation services in 
resource-limited settings.
Methods. Demographic and smoking-related data were collected prospectively from all clinic attendees since its inception. Nicotine 
dependence, depression scores and exhaled carbon monoxide levels were formally evaluated. Consent was provided to review the data 
collected.
Results. Ninety-seven smokers were evaluated. Their mean (standard deviation) age was 50.9 (10.7) years, and 59% (57/97) were male. The 
median age of smoking initiation was 16 years (interquartile range (IQR) 8 - 28), with a current median daily consumption of 12 cigarettes 
(IQR 7 - 20). Overall, men smoked more than women, with a median of 20 cigarettes per day (IQR 10 - 20) v. 12 (IQR 5 - 20), respectively 
(p=0.001). The median Fagerström nicotine dependence score was 5 (IQR 3 - 7), with scores of 6 (IQR 4 - 8) for men and 5 (2 - 7) for 
women (p=0.06); 50% of smokers had a Fagerström score <6 (low to above-average dependence) and 22% a score ≥8 (extreme dependence). 
The median Patient Health Questionnnaire-9 (PHQ-9) depression score was 8 (IQR 4 - 11), and 49% of smokers had symptoms of at least 
minor depression (score ≥10). The clinic could not provide pharmacotherapy. The self-reported quit rate was 28% at median follow-up of 
22 months (IQR 14 - 39).
Conclusions. In smokers attempting to quit, moderate levels of nicotine dependence coexist with significant depression and anxiety 
symptoms. These data inform resource allocation and public health strategies, suggesting that in resource-limited smoking cessation 
services, psychological/behavioural support focusing on depressive symptoms may be a greater priority than simple pharmacotherapy.
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odds of long-term cessation. There are, however, no data to indicate 
who will be unsuccessful if pharmacotherapy is not added to 
behavioural interventions.
Objectives
A dedicated smoking cessation clinic established at Groote Schuur 
Hospital (GSH) in Cape Town is the only one of its kind in SA. Our 
objectives were to to assess the sociodemographic and dependency 
profiles of the smokers who attended this clinic and their short- and 
long-term outcomes. By understanding the characteristics and needs 
of smokers in this setting, we hoped to provide relevant data to help 
guide locally applicable smoking cessation services applicable in 
LMICs. Identifying factors that support successful quitting, and those 
that act as barriers, is imperative in understanding the requirements 
for psychological and pharmacological support in such services.
Methods
Establishing the clinic
The first SA smoking cessation clinical practice guidelines were 
published in 2013.[19] Prior to this date and the establishment of the 
GSH clinic in December 2012, no formal smoking cessation services 
existed in the public sector. No pharmacotherapy was available 
for smoking cessation in government hospitals, and availability of 
nicotine patches was very limited owing to available products being 
withdrawn from SA. With permission from the Head of the Division 
of Pulmonology at GSH, a specialised clinic was introduced to offer 
evaluation of and smoking cessation support to any smoker wishing 
to quit. The clinic was established within the respiratory outpatient 
services for convenience, as the trained staff were from the Division 
of Pulmonology and the clinic was physically near the cardiology 
outpatients and transplant services. The doctors had received limited 
smoking cessation training at a variety of local workshops, and a 
nursing sister was trained to provide additional counselling. No 
specialist psychological/psychiatric support or pharmacotherapy was 
available in the clinic.
The study reviewed data collected from all smokers attending 
GSH’s smoking cessation clinic since its inception. New patient data 
collection commenced when the clinic opened in 2012 and was 
truncated in September 2016. A pre-formed data capturing sheet 
to guide the consultation and to assimilate the required smoking 
cessation-specific information was used. Self-reported scales 
(Fagerström, Patient Health Questionnnaire-9 (PHQ-9), etc.) were 
completed by the individual person, with the remaining evaluation 
completed by the attending doctor. Information captured included 
age, motivation to quit, tobacco smoking history, medical history, 
Fagerström score, Wisconsin withdrawal score, PHQ-9 depression 
score and perceived medication affordability. Carbon monoxide 
(CO) levels were tested using a piCO Smokerlyzer (Bedfont, UK) at 
each visit.
Interventions
After completing the prespecified questionnaires, all attendees were 
seen by a doctor (pulmonologist or medical registrar). Basic smoking 
history was confirmed, and level of motivation and reasons for 
wishing to quit were evaluated. Counselling was performed by the 
doctor, as there were limited alternative counselling personnel. 
Counselling included evaluation of previous attempts to quit and 
reasons for relapse or failure. Information on nicotine dependence 
was provided, as well as on the importance of behavioural change 
and pharmacotherapy if needed. Interviews were conducted in 
a motivational interviewing style directed towards behavioural 
change with a specific focus on self-motivation, problem solving and 
strategies for coping with withdrawal symptoms.
Ethical considerations
Ethics approval to perform this clinical patient database review was 
granted by the University of Cape Town Faculty of Health Sciences 
Human Research Ethics Committee (ref. no. 667/205) and GSH 
administration. At the time of their first visit, all patients provided 
written informed consent to have their data relevant to the smoking 
cessation clinic collected as part of the standard evaluation of all 
patients at the clinic. Participants also provided contact details to allow 
for telephonic contact to provide support and evaluate outcomes.
Statistical analysis
Data were entered onto an electronic database and independently 
reviewed for accuracy. Analysis was conducted using Graphpad 
prism 5.0 for Mac OSX (GraphPad Software, USA) and Stata  13 
(StataCorp, USA). Continuous data were expressed as means 
(standard deviations (SDs)) or medians with interquartile ranges 
(IQRs). For categorical data, the χ2 test or Fisher’s exact test was 
used. The Mann-Whitney test or Student’s t-test was used to test the 
association between continuous and categorical variables. A p-value 
of 0.05 was used to determine statistical significance.
Results
Participants
The weekly smoking cessation clinic received the majority of its 
referrals from cardiology, respiratory and other tertiary clinics (organ 
transplant, infertility) at GSH. A few attendees were ‘healthy smokers’ 
from outside the hospital. During the audit review, 98 smokers 
attended for at least one visit. Only 1 attendee did not complete the 
requisite forms and was not included in any of the analyses.
Detailed characteristics of the patients attending the clinic are 
reported in Table 1. There was a predominance of male smokers (60%, 
58/97). The mean (SD) age of attendees was 51.1 (10.9) years. There 
was no difference in the age of men compared with women, and the 
median age of smoking initiation was similar at 16 years (IQR 8 - 28). 
On average, men smoked more cigarettes per day than women (median 
20 (IQR 10 - 20) v. 12 (IQR 5 - 20), respectively; p=0.001), resulting in 
higher cumulative total pack-years of smoking at the time of the first 
visit (33 (IQR 20 - 45) v. 21 (IQR 7 - 33); p=0.001). However, at the time 
of the first visit the majority of attendees were smoking 12 cigarettes per 
day on average. The most frequent motive noted for quitting was, not 
unexpectedly, health reasons (Table 2).
The majority of attendees had previously tried to quit: 91% had 
made at least one attempt within the past year, with 48% making more 
than four attempts in the past 12 months. Only 8% reported having 
previously used pharmacotherapy in a quit attempt. Of the attendees, 
68% lived with other smokers in the house. One-third (32%) indicated 
at the initial visit that they could potentially afford to purchase 
medication privately to assist with the quit attempt (Table 2).
Nicotine dependence was evaluated using the Fagerström Test. [20] 
The median score was 6 (IQR 3 - 7). Women had slightly lower 
scores than men (median 5 (IQR 2 - 7) v. 6 (IQR 4 - 8), respectively; 
p=0.06), as shown in Table 2. However, 50% of smokers had a score 
of 4 - 5, indicating ‘above-average’ dependence, and 23% had a score 
>8, indicating ‘extreme dependence’ (Fig. 1). Exhaled CO levels were 
similar in men and women, with a mean (SD) score of 15.9 (9.1) 
parts per million. Exhaled CO correlated positively with current 
tobacco consumption (Spearman’s r=0.52 (95% confidence interval 
(CI) 0.28  - 0.70); p<0.001)) and with Fagerström scores, although 
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less strongly (r=0.41 (95% CI 0.15 - 0.62); p=0.02). Current number 
of cigarettes per day correlated strongly with the Fagerström score 
(r=0.74 (95% CI 0.62 - 0.82); p<0.001) (Fig. 2). Motivation to quit 
was reported as high, and there was no difference in in that regard 
between men and women.
Depressive symptoms were prospectively evaluated, and complete 
scores were evaluable for 55 attendees at the first visit using the 
PHQ-9 depression test. Nearly two-thirds (63%) of smokers reported 
at least minor symptoms of depression when screened at the first 
visit, and 38% (21/55) expressed symptoms of at least moderately 
severe depression (score ≥15) (Fig. 3); 18% (10/55) would be 
classified as severely depressed based on the PHQ-9 score. Evaluating 
the individual specified subcategories making up the Wisconsin 
Withdrawal Scale at the initial visit (when the participants were still 
smoking), patients had on average high (>2/4) subscores for anger, 
anxiety and sadness (Table 2).
Smokers who had attended the clinic were contacted by telephone 
in 2016/17. Using the contact numbers provided at the first visit, 
only 46 (47%) of the 97 attendees were contactable. The median 
time to follow-up was 22.5 months (IQR 14 - 39) after the first clinic 
visit. Based on self-reported smoking status, 13 attendees (28%) had 
successfully quit, 33 (72%) were still smoking, and 2 were stated 
to have died (cause not reported). Although the review was not 
specifically powered to evaluate predictors of outcome, individuals 
who had successfully quit had lower mean (SD) PHQ-9 depression 
scores than those who had been unsuccessful (3.9 (1.9) v. 7.1 (1.0), 
Table 1. Attendee characteristics
Characteristics Female (N=39, 40%) Male (N=58, 60%) Total (N=97)
Current age (years), mean (SD) 48.5 (9.5) 52.4 (11.3) 50.9 (10.7)
Age at smoking initiation (years), median (IQR) 16 (15 - 19) 16 (14 - 18) 16 (14.5 - 18)
Total years smoked, mean (SD) 31.7 (10.1) 34.7 (11.9) 33.5 (11.3)
Average number per day smoked, median (IQR) 12 (5 - 20)* 20 (10 - 20)* 20 (10 - 20)
Current number per day smoked, median (IQR) 11 (8 - 17) 15 (6 - 25) 12 (7 - 20)
Total pack-years smoked, median (IQR) 21 (7 - 33)* 33 (20 - 45)* 29.5 (12.5 - 40)
Previous attempt to quit smoking, n (%) 32 (82) 43 (75) 75 (78)
Quit attempts in the past year, n (%)
None 3 (8) 6 (11) 9 (9)
1 - 4 18 (46) 23 (40) 41 (43)
>4 18 (46) 28 (49) 46 (48)
Lives with smoker in house, n (%) 28 (72) 37 (65) 65 (68)
Number of smokers in house, n (%)
0 11 (28) 20 (35) 31 (32)
1 - 2 17 (44) 21 (37) 38 (40)
>2 11 (28) 16 (28) 27 (28)
SD = standard deviation; IQR = interquartile range.
*p<0.05.
Table 2. Dependence and barriers to quitting smoking
Variable Female Male Total
Fagerström dependence score (N=90), median (IQR) 5 (2 - 7)* 6 (4 - 8)* 6 (3 - 7)
Exhaled CO (ppm), median (IQR) 15 (9 - 23) 14 (9 - 20) 14.5 (9 - 20)
Motivation score (1 - 10), median (IQR) 10 (8 - 10) 10 (6 - 10)   10 (8 - 10)
Reasons for quitting smoking (N=98), n (%)
Personal health 21 (54) 22 (39) 43 (44)
Financial reasons 3 (8) 1 (2) 4 (4)
Family 1 (3) 3 (5) 4 (4) 
Fertility 0 1 (2) 1 (1) 
PHQ-9 depression score (N=55), median (IQR) 8 (4 - 11) 8 (5 - 11) 8 (4 - 11) 
PHQ-9 total score (N=55), n (%) 
0 - 4 9 (41) 6 (18) 15 (27)
5 - 9 8 (36) 11 (33) 19 (35)
10 - 15 2 (9) 9 (27) 11 (20)
>15 3 (14) 7 (21) 10 (18)
Wisconsin Withdrawal Scale subscore, median (IQR) 
Anger (N=87) 2.33 (1.3 - 3) 2 (1.33 - 3.3) 2 (1.3 - 3)
Anxiety (N=90) 2.5 (1.8 - 3) 2.25 (1.3 - 2.8) 2.25 (1.25 - 3)
Sadness (N=89) 2 (1.3 - 2.6) 1.75 (1 - 2.5) 2 (1.25 - 2.5)
Patient could potentially afford to purchase medication (N=87), n (%) 10 (28) 18 (35) 28 (32)
IQR = interquartile range; CO = carbon monoxide; ppm = parts per million; PHQ-9 = PHQ-9 = Patient Health Questionnnaire-9.
*p<0.05.
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respectively; p=0.046). In univariate analysis this translated into a 
trend towards successful quitting with a lower depression score (odds 
ratio 0.86 (95% CI 0.76 - 1.00); p=0.056). There was no difference in 
the number of clinic visits attended by those who quit successfully v. 
those who did not, or in duration of follow-up when contacted. Time 
to first cigarette in the morning was not predictive of success, and no 
difference was seen between quitters and non-quitters with regard to 
baseline nicotine dependence scores (Fagerström score 4 v. 5; p=0.34) 
(Fig. 4, A and B).
Discussion
Access to formal smoking cessation services is very limited in 
LMICs.[16] In this cohort of smokers from a low- to middle-
income population group in SA attending a dedicated smoking 
cessation service, high levels of depressive symptoms were common, 
with accompanying moderate nicotine dependence. Currently no 
pharmacotherapy is provided by the government to assist smokers 
in quitting. Given the high level of depressive symptoms and 
stressors with relatively low nicotine dependence reported by the 
attendees, psychological and behaviour support for smokers should 
be a priority. The role for pharmacological support, given its poor 
availability and high cost, needs to be prospectively determined. 
Despite the lack of pharmacotherapy or specialised psychological 
support to assist in smoking cessation, some patients were successful 
in quitting smoking.
Global smoking cessation guidelines, including the SA guidelines, 
recommend a combination of behavioural support/counselling and 
pharmacotherapy to support smoking cessation attempts.[19,21,22] The 
WHO has placed NRT on the essential medication list, but access 
to pharmacotherapy is severely limited and costly in resource-
constrained settings, even in a middle-income country such as SA.
To date there have been very limited data published on smoking 
cessation clinics in LMICs. The majority of reports are on integrated/
opportunistic brief interventions alongside healthcare services. [16,17] 
Opportunities such as tuberculosis and HIV treatment programmes 
have shown promise as a chance to address tobacco smoking in 
conjunction with treating infectious diseases.[23,24] In many developed-
world settings, in-hospital smoking cessation strategies have been an 
opportunity to commence interventions.[25] What is clear, however, 
is that if patients are not followed up or continued on treatment on 
discharge, all gains during the hospital stay with regard to quitting 
smoking are essentially for naught.
SA has been characterised as the world’s second most stressful 
country to live in, although these data do not include much of 
Africa. [26] If one compares the level of stressors in SA with other 
countries globally, however, Egypt (for example) is ranked 15th, 
Brazil 17th, China 29th, the UK 56th and Australia 70th. During 
counselling of the smokers in our study, common reported stressors 
included personal safety, financial insecurity, health concerns, 
community safety and anxieties regarding the country’s future. These 
concerns may be intensified by a hospitalisation or acute medical 
illness, especially if an additional financial strain and burden is 
precipitated by lack of income and family support.[27] Unexpected 
hospital admissions may therefore not be the best opportunities to 
intervene, given the accompanying heightened stress.
Smokers in our outpatient cohort showed significant levels of 
background depressive symptoms, both on the formal PHQ-9 
depression scoring and also when we evaluated the subscore of the 
Wisconsin Withdrawal Scale (while the attendees were still smoking). 
In active smokers, a balance exists between tobacco/nicotine 
dependence and the psychological/ behavioural habit of smoking 
(although these aspects are not always clearly separable). There is 
strong evidence that counselling and pharmacotherapy go hand in 
hand, with a combination generally better than either alone.[21] What 
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Fig. 1. Fagerström scores for nicotine dependence. (Interpretation of 
dependence scores: 0 - 1 low, 2 - 3 average, 4 - 5 above average, 6 - 7 high, 
8 - 10 extreme nicotine dependence.)
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Fig. 2. Correlation between current daily number of cigarettes smoked 
and Fagerström score for nicotine dependence. Solid line: regression line 
with 95% CI, Spearman’s r=0.74 (95% CI 0.62 - 8.82); p<0.0001. (CI = 
confidence interval.)
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Fig. 3. PHQ-9 depression scores. (Interpretation of PHQ-9 score: 0 - 4 no 
symptoms, 5 - 9 minimal symptoms, 10 - 14 minor depression/major 
depression mild, 15 - 19 major depression moderately severe, >20 major 
depression severe; PHQ-9 = Patient Health Questionnnaire-9.)
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is not clear, and has no literature to support 
it, is how to estimate whether an individual 
will be able to quit without the addition of 
medication. There is a strong correlation 
between Fagerström score and long-term 
cessation success,[28] and specifically time to 
first cigarette in the morning has been shown 
to be a simple measure to use.[28] Additionally, 
underlying depression and poor outcomes are 
correlated in reports from smoking cessation 
services. [29] In our cohort, no significant 
correlation was found between dependence 
indices and outcome, although the audit was 
not primarily powered to evaluate predictors 
of outcome owing to the nature of the 
study. Despite the lack of pharmacotherapy 
long-term quit rates were encouraging, 
although an estimation of true success was 
not possible owing to the excessive loss to 
follow-up and inability to confirm smoking 
status chemically. What was evident in this 
cohort of low-income smokers was the low 
to moderate level of nicotine dependence 
and moderate to high level of depressive 
symptoms. This finding raises the question 
whether it is preferable to spend resources 
on skilled counselling when establishing 
dedicated smoking cessation centres in low-
income settings, or on the provision of NRT/
varenicline/bupropion to aid in quit attempts 
for all patients.
Study limitations
The study has several limitations. Referral 
to the service was encouraged for smokers 
motivated to quit. The service did not have 
on-site specialised counselling for depression 
or anxiety, but relied on referral to such 
services. The level of depressive symptoms 
may be different in individuals who are 
not willing to quit, but the characteristics 
of the attendees presented were of those 
wanting help to stop smoking. It was not 
possible to evaluate whether outcomes 
would have been different if the patients 
had had access to pharmacotherapy. There 
is therefore uncertainty whether to prioritise 
counselling or medication, but the high level 
of depressive symptoms requires attention 
irrespective of smoking status. Follow-up 
was incomplete, as many of the contact 
telephone numbers that were provided did 
not work. Prespecified powered outcome 
calculations were not possible, but patient 
data collection is ongoing.
Recommendations
The questions facing the clinician with 
limited access to pharmacotherapy to assist 
smoking cessation are who should receive 
it, and whether it is possible to predict who 
will not be successful without the provision 
of medication. An approach could be to 
initiate an intensive behaviour motivation 
intervention irrespective of dependence 
scores, and to provide NRT at the second 
attempt for those who fail due to withdrawal 
symptoms. The strategy in our clinic was 
to provide a support service that did not 
previously exist in an attempt to help 
smokers quit, and to gather the necessary 
data to motivate for locally relevant 
psychological and/or pharmacological 
interventions. Based on the data from this 
cohort, attending to the social, financial 
and emotional upheaval described by the 
majority of smokers seen may be of far 
more importance than pharmacotherapy in 
achieving long-term freedom from tobacco 
dependence. Poverty alleviation, sustainable 
income and mental health are not issues that 
can simply be solved by a nicotine patch or 
gum. Providing behavioural tools to assist 
with coping with life stressors, counselling 
and appropriate referral to social services 
is a starting point to explore in low-income 
settings where the behavioural aspects of 
tobacco dependence as a coping mechanism 
may outweigh the pure chemical addiction.
As with all interventions in medicine, 
the certainty with which outcomes/response 
to therapy can be predicted enhances our 
decision-making and ability to motivate to 
funders to support treatment strategies. In 
low-resourced areas, the clinician is bound 
to equitable resource allocation and often 
provides interventions for those who will 
‘benefit’ the most. If we could reasonably 
identify those who will inevitably fail without 
pharmacotherapy, we could motivate for 
such targeted interventions. Extrapolating 
from the nicotine dependence scores in this 
cohort, ~25% had very high dependence 
and should by any major guideline strategy 
have been receiving pharmacological 
support. The PHQ-9 scores indicative of 
major depression in ~1 in 5 smokers would 
warrant appropriate referral to competent 
psychiatric services before any quit attempt 
is made. Depending on the skills of the 
service providers (doctor v. psychologist), 
these services could be interlinked.
Conclusions
Smoking cessation should be a priority in 
all healthcare services, especially in low-
income settings where smoking results in a 
significant health burden, drives mortality 
rates and consumes substantial disposable 
income among those who can least afford it. 
High levels of depression and social stressors 
existed in our cohort of smokers, suggesting 
that interventions targeting the behavioural 
aspects of tobacco dependence should be 
emphasised and potentially balanced with 
the provision of NRT for those with very 
high dependence. Prospective, scalable and 
cost-effective interventions for tobacco 
dependence are needed to address this major 
modifiable risk factor for communicable and 
non-communicable diseases in low-income 
settings.
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